Urine NGAL Predicts Severity of Acute Kidney Injury After Cardiac Surgery: A Prospective Study

Background and objectives: The authors have previously shown that urine neutrophil gelatinase-associated lipocalin (NGAL), measured by a research ELISA, is an early predictive biomarker of acute kidney injury (AKI) after cardiopulmonary bypass (CPB). In this study, whether an NGAL immunoassay developed for a standardized clinical platform (ARCHITECT analyzer®, Abbott Diagnostics Division, Abbott Laboratories, Abbott Park, IL) can predict AKI after CPB was tested

Plasma NGAL measurements obtained using TriageNGAL device at various time points after CPB

<p><b>Copyright information:</b></p><p>Taken from "Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study"</p><p>http://ccforum.com/content/11/6/R127</p><p>Critical Care 2007;11(6):R127-R127.</p><p>Published online 10 Dec 2007</p><p>PMCID:PMC2246223.</p><p></p> AKI was defined as a 50% increase in serum creatinine from baseline. Values are expressed as means ± standard deviation. *< 0.0001 comparing AKI versus no AKI groups. AKI, acute kidney injury; CPB, cardiopulmonary bypass; NGAL, neutrophil gelatinase-associated lipocalin